HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor
30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.
HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic
Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...
HepaRegeniX GmbH Raises € 9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group...